In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan
Abstract Objectives We investigated the in vitro activities of cefiderocol, ceftazidime/avibactam, ceftolozane/tazobactam and other related drugs against imipenem-resistant Pseudomonas aeruginosa, imipenem-resistant Acinetobacter baumannii and Stenotrophomonas maltophilia isolates. Methods Non-dupli...
Gespeichert in:
| Veröffentlicht in: | Journal of antimicrobial chemotherapy 2019-02, Vol.74 (2), p.380-386 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 386 |
|---|---|
| container_issue | 2 |
| container_start_page | 380 |
| container_title | Journal of antimicrobial chemotherapy |
| container_volume | 74 |
| creator | Hsueh, Shun-Chung Lee, Yuarn-Jang Huang, Yu-Tsung Liao, Chun-Hsing Tsuji, Masakatsu Hsueh, Po-Ren |
| description | Abstract
Objectives
We investigated the in vitro activities of cefiderocol, ceftazidime/avibactam, ceftolozane/tazobactam and other related drugs against imipenem-resistant Pseudomonas aeruginosa, imipenem-resistant Acinetobacter baumannii and Stenotrophomonas maltophilia isolates.
Methods
Non-duplicated bacteraemia isolates (n = 300) of imipenem-resistant P. aeruginosa (n = 100), imipenem-resistant A. baumannii (n = 100) and S. maltophilia (n = 100) were evaluated. Imipenem-resistant P. aeruginosa and imipenem-resistant A. baumannii isolates were defined as isolates exhibiting imipenem MIC ≥8 mg/L, as determined using the VITEK 2 system. The MICs of 11 other antimicrobial agents for the isolates were determined by the broth microdilution method. Iron-depleted CAMHB was used to determine the MICs of cefiderocol.
Results
The rates of colistin resistance of imipenem-resistant P. aeruginosa and imipenem-resistant A. baumannii were 5% and 10%, respectively. The MIC90 values of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam, tigecycline and colistin were as follows: imipenem-resistant P. aeruginosa: 1, 4, 16, >4 and 2 mg/L; imipenem-resistant A. baumannii: 8, >64, >64, 4 and 2 mg/L; and S. maltophilia: 0.25, >64, >64, 2 and >8 mg/L, respectively. For imipenem-resistant A. baumannii isolates, the MICs of cefiderocol, ceftolozane/tazobactam and ceftazidime/avibactam were ≤4 mg/L for 88%, 8% and 1% of the isolates, respectively. Cefiderocol MICs were ≤4 mg/L for the five colistin-resistant imipenem-resistant P. aeruginosa isolates and 70% of the 10 colistin-resistant imipenem-resistant A. baumannii isolates.
Conclusions
Cefiderocol exhibited more potent in vitro activity than ceftolozane/tazobactam and ceftazidime/avibactam against imipenem-resistant P. aeruginosa, imipenem-resistant A. baumannii and S. maltophilia isolates. |
| doi_str_mv | 10.1093/jac/dky425 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2125299367</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/jac/dky425</oup_id><sourcerecordid>2125299367</sourcerecordid><originalsourceid>FETCH-LOGICAL-c232t-4d6cc474d6e820fb5291a69b0a23940429aff5bfd07d03c4892f2503351bab373</originalsourceid><addsrcrecordid>eNp9kstv1DAQxgMC0aVwgTvyBQmhhnXsPDbHquJRqRJIlHM0sSfdKbGd2k6r7l-Pd7Nw5DQP__zZY39Z9qbgnwreyvUtqLX-_ViK6mm2Ksqa54K3xbNsxSWv8qas5En2MoRbznld1ZsX2YnksmpkKVdP3l5adk_ROwYqUsoIA3MDUziQRu-UG8_2RXSj24HFdYSd6xMLZunDjjQZXMM9LW0GVjMXt-iZcmYCD0kXmfbzTWBwA2RDZGRoQosm9xgoRLCR_Qg4a2echYRhosm6AAe1c0UW4-HYpNrDbMBaorPD4s-I1qUBpu1xs4ExpopGgkSMI4MQnCKIqNkDxS3rR-d0iB7TZckOmAZ3NqSUXQM9gH2VPR9gDPj6GE-zX18-X198y6--f728OL_KlZAi5qWulSqbFHAj-NBXoi2gbnsOQrYlL0ULw1D1g-aN5lKVm1YMouJSVkUPvWzkafZh0Z28u5sxxM5QUDiO6Z3dHDpRiKTZynqPflxQ5V0IHodu8mTAP3YF7_Ym6JIJusUECX531J17g_of-vfXE_B-Adw8_U_oDwi-w3g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2125299367</pqid></control><display><type>article</type><title>In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><source>Free Full-Text Journals in Chemistry</source><creator>Hsueh, Shun-Chung ; Lee, Yuarn-Jang ; Huang, Yu-Tsung ; Liao, Chun-Hsing ; Tsuji, Masakatsu ; Hsueh, Po-Ren</creator><creatorcontrib>Hsueh, Shun-Chung ; Lee, Yuarn-Jang ; Huang, Yu-Tsung ; Liao, Chun-Hsing ; Tsuji, Masakatsu ; Hsueh, Po-Ren</creatorcontrib><description>Abstract
Objectives
We investigated the in vitro activities of cefiderocol, ceftazidime/avibactam, ceftolozane/tazobactam and other related drugs against imipenem-resistant Pseudomonas aeruginosa, imipenem-resistant Acinetobacter baumannii and Stenotrophomonas maltophilia isolates.
Methods
Non-duplicated bacteraemia isolates (n = 300) of imipenem-resistant P. aeruginosa (n = 100), imipenem-resistant A. baumannii (n = 100) and S. maltophilia (n = 100) were evaluated. Imipenem-resistant P. aeruginosa and imipenem-resistant A. baumannii isolates were defined as isolates exhibiting imipenem MIC ≥8 mg/L, as determined using the VITEK 2 system. The MICs of 11 other antimicrobial agents for the isolates were determined by the broth microdilution method. Iron-depleted CAMHB was used to determine the MICs of cefiderocol.
Results
The rates of colistin resistance of imipenem-resistant P. aeruginosa and imipenem-resistant A. baumannii were 5% and 10%, respectively. The MIC90 values of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam, tigecycline and colistin were as follows: imipenem-resistant P. aeruginosa: 1, 4, 16, >4 and 2 mg/L; imipenem-resistant A. baumannii: 8, >64, >64, 4 and 2 mg/L; and S. maltophilia: 0.25, >64, >64, 2 and >8 mg/L, respectively. For imipenem-resistant A. baumannii isolates, the MICs of cefiderocol, ceftolozane/tazobactam and ceftazidime/avibactam were ≤4 mg/L for 88%, 8% and 1% of the isolates, respectively. Cefiderocol MICs were ≤4 mg/L for the five colistin-resistant imipenem-resistant P. aeruginosa isolates and 70% of the 10 colistin-resistant imipenem-resistant A. baumannii isolates.
Conclusions
Cefiderocol exhibited more potent in vitro activity than ceftolozane/tazobactam and ceftazidime/avibactam against imipenem-resistant P. aeruginosa, imipenem-resistant A. baumannii and S. maltophilia isolates.</description><identifier>ISSN: 0305-7453</identifier><identifier>EISSN: 1460-2091</identifier><identifier>DOI: 10.1093/jac/dky425</identifier><identifier>PMID: 30357343</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Acinetobacter baumannii - drug effects ; Anti-Bacterial Agents - pharmacology ; Azabicyclo Compounds - pharmacology ; Bacteremia - microbiology ; Cefiderocol ; Ceftazidime - pharmacology ; Cephalosporins - pharmacology ; Drug Combinations ; Drug Resistance, Multiple, Bacterial ; Humans ; Imipenem - pharmacology ; Microbial Sensitivity Tests ; Pseudomonas aeruginosa - drug effects ; Stenotrophomonas maltophilia - drug effects ; Taiwan ; Tazobactam - pharmacology</subject><ispartof>Journal of antimicrobial chemotherapy, 2019-02, Vol.74 (2), p.380-386</ispartof><rights>The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com. 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c232t-4d6cc474d6e820fb5291a69b0a23940429aff5bfd07d03c4892f2503351bab373</citedby><cites>FETCH-LOGICAL-c232t-4d6cc474d6e820fb5291a69b0a23940429aff5bfd07d03c4892f2503351bab373</cites><orcidid>0000-0002-7502-9225</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,1579,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30357343$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hsueh, Shun-Chung</creatorcontrib><creatorcontrib>Lee, Yuarn-Jang</creatorcontrib><creatorcontrib>Huang, Yu-Tsung</creatorcontrib><creatorcontrib>Liao, Chun-Hsing</creatorcontrib><creatorcontrib>Tsuji, Masakatsu</creatorcontrib><creatorcontrib>Hsueh, Po-Ren</creatorcontrib><title>In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan</title><title>Journal of antimicrobial chemotherapy</title><addtitle>J Antimicrob Chemother</addtitle><description>Abstract
Objectives
We investigated the in vitro activities of cefiderocol, ceftazidime/avibactam, ceftolozane/tazobactam and other related drugs against imipenem-resistant Pseudomonas aeruginosa, imipenem-resistant Acinetobacter baumannii and Stenotrophomonas maltophilia isolates.
Methods
Non-duplicated bacteraemia isolates (n = 300) of imipenem-resistant P. aeruginosa (n = 100), imipenem-resistant A. baumannii (n = 100) and S. maltophilia (n = 100) were evaluated. Imipenem-resistant P. aeruginosa and imipenem-resistant A. baumannii isolates were defined as isolates exhibiting imipenem MIC ≥8 mg/L, as determined using the VITEK 2 system. The MICs of 11 other antimicrobial agents for the isolates were determined by the broth microdilution method. Iron-depleted CAMHB was used to determine the MICs of cefiderocol.
Results
The rates of colistin resistance of imipenem-resistant P. aeruginosa and imipenem-resistant A. baumannii were 5% and 10%, respectively. The MIC90 values of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam, tigecycline and colistin were as follows: imipenem-resistant P. aeruginosa: 1, 4, 16, >4 and 2 mg/L; imipenem-resistant A. baumannii: 8, >64, >64, 4 and 2 mg/L; and S. maltophilia: 0.25, >64, >64, 2 and >8 mg/L, respectively. For imipenem-resistant A. baumannii isolates, the MICs of cefiderocol, ceftolozane/tazobactam and ceftazidime/avibactam were ≤4 mg/L for 88%, 8% and 1% of the isolates, respectively. Cefiderocol MICs were ≤4 mg/L for the five colistin-resistant imipenem-resistant P. aeruginosa isolates and 70% of the 10 colistin-resistant imipenem-resistant A. baumannii isolates.
Conclusions
Cefiderocol exhibited more potent in vitro activity than ceftolozane/tazobactam and ceftazidime/avibactam against imipenem-resistant P. aeruginosa, imipenem-resistant A. baumannii and S. maltophilia isolates.</description><subject>Acinetobacter baumannii - drug effects</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Azabicyclo Compounds - pharmacology</subject><subject>Bacteremia - microbiology</subject><subject>Cefiderocol</subject><subject>Ceftazidime - pharmacology</subject><subject>Cephalosporins - pharmacology</subject><subject>Drug Combinations</subject><subject>Drug Resistance, Multiple, Bacterial</subject><subject>Humans</subject><subject>Imipenem - pharmacology</subject><subject>Microbial Sensitivity Tests</subject><subject>Pseudomonas aeruginosa - drug effects</subject><subject>Stenotrophomonas maltophilia - drug effects</subject><subject>Taiwan</subject><subject>Tazobactam - pharmacology</subject><issn>0305-7453</issn><issn>1460-2091</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kstv1DAQxgMC0aVwgTvyBQmhhnXsPDbHquJRqRJIlHM0sSfdKbGd2k6r7l-Pd7Nw5DQP__zZY39Z9qbgnwreyvUtqLX-_ViK6mm2Ksqa54K3xbNsxSWv8qas5En2MoRbznld1ZsX2YnksmpkKVdP3l5adk_ROwYqUsoIA3MDUziQRu-UG8_2RXSj24HFdYSd6xMLZunDjjQZXMM9LW0GVjMXt-iZcmYCD0kXmfbzTWBwA2RDZGRoQosm9xgoRLCR_Qg4a2echYRhosm6AAe1c0UW4-HYpNrDbMBaorPD4s-I1qUBpu1xs4ExpopGgkSMI4MQnCKIqNkDxS3rR-d0iB7TZckOmAZ3NqSUXQM9gH2VPR9gDPj6GE-zX18-X198y6--f728OL_KlZAi5qWulSqbFHAj-NBXoi2gbnsOQrYlL0ULw1D1g-aN5lKVm1YMouJSVkUPvWzkafZh0Z28u5sxxM5QUDiO6Z3dHDpRiKTZynqPflxQ5V0IHodu8mTAP3YF7_Ym6JIJusUECX531J17g_of-vfXE_B-Adw8_U_oDwi-w3g</recordid><startdate>20190201</startdate><enddate>20190201</enddate><creator>Hsueh, Shun-Chung</creator><creator>Lee, Yuarn-Jang</creator><creator>Huang, Yu-Tsung</creator><creator>Liao, Chun-Hsing</creator><creator>Tsuji, Masakatsu</creator><creator>Hsueh, Po-Ren</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7502-9225</orcidid></search><sort><creationdate>20190201</creationdate><title>In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan</title><author>Hsueh, Shun-Chung ; Lee, Yuarn-Jang ; Huang, Yu-Tsung ; Liao, Chun-Hsing ; Tsuji, Masakatsu ; Hsueh, Po-Ren</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c232t-4d6cc474d6e820fb5291a69b0a23940429aff5bfd07d03c4892f2503351bab373</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Acinetobacter baumannii - drug effects</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Azabicyclo Compounds - pharmacology</topic><topic>Bacteremia - microbiology</topic><topic>Cefiderocol</topic><topic>Ceftazidime - pharmacology</topic><topic>Cephalosporins - pharmacology</topic><topic>Drug Combinations</topic><topic>Drug Resistance, Multiple, Bacterial</topic><topic>Humans</topic><topic>Imipenem - pharmacology</topic><topic>Microbial Sensitivity Tests</topic><topic>Pseudomonas aeruginosa - drug effects</topic><topic>Stenotrophomonas maltophilia - drug effects</topic><topic>Taiwan</topic><topic>Tazobactam - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hsueh, Shun-Chung</creatorcontrib><creatorcontrib>Lee, Yuarn-Jang</creatorcontrib><creatorcontrib>Huang, Yu-Tsung</creatorcontrib><creatorcontrib>Liao, Chun-Hsing</creatorcontrib><creatorcontrib>Tsuji, Masakatsu</creatorcontrib><creatorcontrib>Hsueh, Po-Ren</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of antimicrobial chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hsueh, Shun-Chung</au><au>Lee, Yuarn-Jang</au><au>Huang, Yu-Tsung</au><au>Liao, Chun-Hsing</au><au>Tsuji, Masakatsu</au><au>Hsueh, Po-Ren</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan</atitle><jtitle>Journal of antimicrobial chemotherapy</jtitle><addtitle>J Antimicrob Chemother</addtitle><date>2019-02-01</date><risdate>2019</risdate><volume>74</volume><issue>2</issue><spage>380</spage><epage>386</epage><pages>380-386</pages><issn>0305-7453</issn><eissn>1460-2091</eissn><abstract>Abstract
Objectives
We investigated the in vitro activities of cefiderocol, ceftazidime/avibactam, ceftolozane/tazobactam and other related drugs against imipenem-resistant Pseudomonas aeruginosa, imipenem-resistant Acinetobacter baumannii and Stenotrophomonas maltophilia isolates.
Methods
Non-duplicated bacteraemia isolates (n = 300) of imipenem-resistant P. aeruginosa (n = 100), imipenem-resistant A. baumannii (n = 100) and S. maltophilia (n = 100) were evaluated. Imipenem-resistant P. aeruginosa and imipenem-resistant A. baumannii isolates were defined as isolates exhibiting imipenem MIC ≥8 mg/L, as determined using the VITEK 2 system. The MICs of 11 other antimicrobial agents for the isolates were determined by the broth microdilution method. Iron-depleted CAMHB was used to determine the MICs of cefiderocol.
Results
The rates of colistin resistance of imipenem-resistant P. aeruginosa and imipenem-resistant A. baumannii were 5% and 10%, respectively. The MIC90 values of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam, tigecycline and colistin were as follows: imipenem-resistant P. aeruginosa: 1, 4, 16, >4 and 2 mg/L; imipenem-resistant A. baumannii: 8, >64, >64, 4 and 2 mg/L; and S. maltophilia: 0.25, >64, >64, 2 and >8 mg/L, respectively. For imipenem-resistant A. baumannii isolates, the MICs of cefiderocol, ceftolozane/tazobactam and ceftazidime/avibactam were ≤4 mg/L for 88%, 8% and 1% of the isolates, respectively. Cefiderocol MICs were ≤4 mg/L for the five colistin-resistant imipenem-resistant P. aeruginosa isolates and 70% of the 10 colistin-resistant imipenem-resistant A. baumannii isolates.
Conclusions
Cefiderocol exhibited more potent in vitro activity than ceftolozane/tazobactam and ceftazidime/avibactam against imipenem-resistant P. aeruginosa, imipenem-resistant A. baumannii and S. maltophilia isolates.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>30357343</pmid><doi>10.1093/jac/dky425</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-7502-9225</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0305-7453 |
| ispartof | Journal of antimicrobial chemotherapy, 2019-02, Vol.74 (2), p.380-386 |
| issn | 0305-7453 1460-2091 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2125299367 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection; Free Full-Text Journals in Chemistry |
| subjects | Acinetobacter baumannii - drug effects Anti-Bacterial Agents - pharmacology Azabicyclo Compounds - pharmacology Bacteremia - microbiology Cefiderocol Ceftazidime - pharmacology Cephalosporins - pharmacology Drug Combinations Drug Resistance, Multiple, Bacterial Humans Imipenem - pharmacology Microbial Sensitivity Tests Pseudomonas aeruginosa - drug effects Stenotrophomonas maltophilia - drug effects Taiwan Tazobactam - pharmacology |
| title | In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T09%3A38%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20vitro%20activities%20of%20cefiderocol,%20ceftolozane/tazobactam,%20ceftazidime/avibactam%20and%20other%20comparative%20drugs%20against%20imipenem-resistant%20Pseudomonas%20aeruginosa%20and%20Acinetobacter%20baumannii,%20and%20Stenotrophomonas%20maltophilia,%20all%20associated%20with%20bloodstream%20infections%20in%20Taiwan&rft.jtitle=Journal%20of%20antimicrobial%20chemotherapy&rft.au=Hsueh,%20Shun-Chung&rft.date=2019-02-01&rft.volume=74&rft.issue=2&rft.spage=380&rft.epage=386&rft.pages=380-386&rft.issn=0305-7453&rft.eissn=1460-2091&rft_id=info:doi/10.1093/jac/dky425&rft_dat=%3Cproquest_cross%3E2125299367%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2125299367&rft_id=info:pmid/30357343&rft_oup_id=10.1093/jac/dky425&rfr_iscdi=true |